Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Total Debt (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Total Debt over the past 15 years, most recently at $5.8 million for Q2 2025.

  • For Q2 2025, Total Debt fell 94.29% year-over-year to $5.8 million; the TTM value through May 2025 reached $5.8 million, down 94.29%, while the annual FY2025 figure was $5.8 million, 94.29% down from the prior year.
  • Total Debt for Q2 2025 was $5.8 million at Lifecore Biomedical, Inc. \De\, down from $115.7 million in the prior quarter.
  • Over five years, Total Debt peaked at $193.9 million in Q2 2021 and troughed at $5.8 million in Q2 2025.
  • A 5-year average of $94.8 million and a median of $98.6 million in 2022 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: soared 506.93% in 2024 and later tumbled 94.29% in 2025.
  • Year by year, Total Debt stood at $166.2 million in 2021, then tumbled by 40.46% to $99.0 million in 2022, then crashed by 82.16% to $17.7 million in 2023, then crashed by 47.46% to $9.3 million in 2024, then crashed by 37.44% to $5.8 million in 2025.
  • Business Quant data shows Total Debt for LFCR at $5.8 million in Q2 2025, $115.7 million in Q1 2025, and $9.3 million in Q4 2024.